Is there any data in the literature on the incidence of COVID-19 in patients taking hydroxychloroquine as a basic therapy for rheumatoid arthritis or lupus?
This data could give important information regarding the effectiveness of chemoprophylaxis.
This is a great question! it is likely that we will have these data retrospectively through rheumatology studies (in Europe) and/or infectious disease investigations (e.g. in developing countries). Matteo Nioi
Safer, faster, without ethical repercussions and cheaper than a 'ex novo' trial ... The main limit would be the pre-existing rheumatological pathology ... However I think it could be useful and interesting ...
… @pietronapoli
Hi
Please check the following work. It describes the process in details. I believe it will help you.
https://academic.oup.com/ofid/article/7/4/ofaa130/5820538
Regards
This will give us an important data regarding chemo prophylactic use of hydroxychloroquine. As of now no such data is available, ICMR recommended HCQ prophylaxis for health care worker and Asymptomatic contacts of Lab confirmed COVID positive case depending on preclinical studies.
Thank you for the answers, very interesting. I know the discussions about the use of hydroxychloroquine, but I wanted to know specifically if there are studies that examine patients who take it as a basic therapy.
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
The above publication describes the course of COVID-19 in 17 patients with SLE while on long-term hydroxychloroquine (1). As there was no comparative group, no conclusions can be drawn on the protective effect of hydroxychloroquine.
At least a case controlled study of rheumatology patients with COVID-19 infection while on Hydroxychloroquine compared to such patients not on Hydroxychloroquine will be needed.
May be COVID-19 infection in a large cohort of SLE, Rheumatoid arthritis, and dermatitis some of them not on hydroxychloroquine may bridge such knowledge gap.
1. https://ard.bmj.com/content/early/2020/04/24/annrheumdis-2020-217566
The following articles can be helpful
1. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30095-3/fulltext
2. https://ard.bmj.com/content/79/6/e62
3. https://ard.bmj.com/content/early/2020/05/22/annrheumdis-2020-217615
A tedious effort failed to find out any document that reveals the incidence of COVID-19 in patients taking hydroxychloroquine for rheumatological diseases.